169 related articles for article (PubMed ID: 24627909)
1. Epigenetic modification boosts ovarian cancer vaccination.
Benmaamar R
Lancet Oncol; 2014 Feb; 15(2):e55. PubMed ID: 24627909
[No Abstract] [Full Text] [Related]
2. Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer.
Odunsi K; Matsuzaki J; James SR; Mhawech-Fauceglia P; Tsuji T; Miller A; Zhang W; Akers SN; Griffiths EA; Miliotto A; Beck A; Batt CA; Ritter G; Lele S; Gnjatic S; Karpf AR
Cancer Immunol Res; 2014 Jan; 2(1):37-49. PubMed ID: 24535937
[TBL] [Abstract][Full Text] [Related]
3. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
[TBL] [Abstract][Full Text] [Related]
4. Will next-generation agents deliver on the promise of epigenetic hypomethylation therapy?
Lowder JN; Taverna P; Issa JP
Epigenomics; 2015 Oct; 7(7):1083-8. PubMed ID: 26541345
[No Abstract] [Full Text] [Related]
5. Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors.
Cowan LA; Talwar S; Yang AS
Epigenomics; 2010 Feb; 2(1):71-86. PubMed ID: 22122748
[TBL] [Abstract][Full Text] [Related]
6. [Epigenetic therapy in myelodysplastic syndromes (MDS). Treatment with DNA methyltransferase inhibitors].
Daskalakis M; Blagitko-Dorfs N; Hackanson B; Lübbert M
Pharm Unserer Zeit; 2010 May; 39(3):217-27. PubMed ID: 20425776
[No Abstract] [Full Text] [Related]
7. Epigenetic drugs take on cancer.
Kaiser J
Science; 2010 Oct; 330(6004):576-8. PubMed ID: 21030620
[No Abstract] [Full Text] [Related]
8. Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.
Stresemann C; Lyko F
Int J Cancer; 2008 Jul; 123(1):8-13. PubMed ID: 18425818
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic silencing of DKK2 and Wnt signal pathway components in human ovarian carcinoma.
Zhu J; Zhang S; Gu L; Di W
Carcinogenesis; 2012 Dec; 33(12):2334-43. PubMed ID: 22964660
[TBL] [Abstract][Full Text] [Related]
10. Introduction: emerging role of epigenetic therapy: focus on decitabine.
Issa JP; Kantarjian HM
Semin Hematol; 2005 Jul; 42(3 Suppl 2):S1-2. PubMed ID: 16015499
[No Abstract] [Full Text] [Related]
11. Utilization of chromatin remodeling agents for lung cancer therapy.
Schrump DS; Hong JA; Nguyen DM
Cancer J; 2007; 13(1):56-64. PubMed ID: 17464247
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
[TBL] [Abstract][Full Text] [Related]
13. Promoter hypermethylation influences the suppressive role of maternally expressed 3, a long non-coding RNA, in the development of epithelial ovarian cancer.
Sheng X; Li J; Yang L; Chen Z; Zhao Q; Tan L; Zhou Y; Li J
Oncol Rep; 2014 Jul; 32(1):277-85. PubMed ID: 24859196
[TBL] [Abstract][Full Text] [Related]
14. Targeting DNA methylation.
Issa JP; Kantarjian HM
Clin Cancer Res; 2009 Jun; 15(12):3938-46. PubMed ID: 19509174
[TBL] [Abstract][Full Text] [Related]
15. DNA methyltransferase inhibitors for cancer therapy.
Brueckner B; Kuck D; Lyko F
Cancer J; 2007; 13(1):17-22. PubMed ID: 17464242
[TBL] [Abstract][Full Text] [Related]
16. The role of epigenetics in cancer. DNA Methylation, Imprinting and the Epigenetics of Cancer--an American Association for Cancer Research Special Conference. Las Croabas, Puerto Rico, 12-16 1997 December.
Lengauer C; Issa JP
Mol Med Today; 1998 Mar; 4(3):102-3. PubMed ID: 9575489
[No Abstract] [Full Text] [Related]
17. Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report.
Fan H; Lu X; Wang X; Liu Y; Guo B; Zhang Y; Zhang W; Nie J; Feng K; Chen M; Zhang Y; Wang Y; Shi F; Fu X; Zhu H; Han W
J Immunol Res; 2014; 2014():371087. PubMed ID: 24963497
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic therapies move into new territory, but how exactly do they work?
Tuma RS
J Natl Cancer Inst; 2009 Oct; 101(19):1300-1. PubMed ID: 19755677
[No Abstract] [Full Text] [Related]
19. BORIS/CTCFL expression is insufficient for cancer-germline antigen gene expression and DNA hypomethylation in ovarian cell lines.
Woloszynska-Read A; James SR; Song C; Jin B; Odunsi K; Karpf AR
Cancer Immun; 2010 Jul; 10():6. PubMed ID: 20649179
[TBL] [Abstract][Full Text] [Related]
20. DNA methyltransferase inhibitors in cancer: a chemical and therapeutic patent overview and selected clinical studies.
Fahy J; Jeltsch A; Arimondo PB
Expert Opin Ther Pat; 2012 Dec; 22(12):1427-42. PubMed ID: 23033952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
